top of page

News
Search


TestAVec presenting at ESGCT 2024
TestAVec's chairman, Mr Robert Spencer, and Chief Scientific Officer, Prof. Micahel Themis, will be attending this year's congress of the...
Oct 15, 2024


Consensus Paper Calls for Regulatory Framework Development in Genotoxicity Analysis of Gene Therapy Vectors
In March 2023, the NC3Rs and UKEMS hosted a groundbreaking meeting, originally conceived by TestAVec and Novartis, of top experts in gene...
Aug 5, 2024


Testavec appoints new Director to Drive business growth
DAVID LASKOW-POOLEY JOINS BOARD OF TESTAVEC LTD David Laskow- Pooley has joined the company to accelerate the commercialisation of the...
Aug 1, 2024


TestAVec researchers devise new protocols to generate high titre HIV-1 lentivirus vectors in a cost efficient and scalable method
TestAVec researchers, lead by CSO Professor Michael Themis, have devised new protocols for making high titre HIV-1 lentivirus particles...
Feb 1, 2024


Happy holidays from the TestAVec team
From all of us here at TestAVec, we wish you a happy holiday season and new year. Time to enjoy the festive period and go into 2024 to...
Dec 25, 2023
bottom of page